Another example showing the ridiculous price we are being offered for Viralytics.
Johnson and Johnson bought PRE-CLINICAL oncolytic Virus Company, Benevir today for $140M US up front and $900M US more in potential milestone payments.
This is preclinical, NO HUMAN results!
Great Human phase II data like CAVATAC has should be worth 5-10x preclinical assets of similar type.
Merck is getting Viralytics for $500M AUS, which is $375M US and no future revenue streams for the current shareholders.
BOD should have done a better job!
https://www.pharmpro.com/news/2018/05/johnson-johnson-acquire-benevir-biopharm
another virus bought!!!
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
